Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Achyut Healthcare, a pharmaceutical trading company listed on BSE SME, announced its H1 FY26 (April–September 2025) results approved by the board on 16 October 2025. Revenue from operations jumped to Rs. 212.66 lakhs from Rs. 96.61 lakhs in the same period last year, a growth of around 120%. Net profit rose to Rs. 23.30 lakhs from Rs. 11.95 lakhs, nearly doubling year-on-year. Profit before tax stood at Rs. 31.23 lakhs (vs. Rs. 23.12 lakhs in H1 FY25). Operating cash flow turned positive at Rs. 124.57 lakhs, a sharp swing from negative Rs. 406.41 lakhs in FY25. The statutory auditor, Doshi Doshi & Co, issued a clean limited review report with no qualifications or adverse remarks.
Strong top-line and bottom-line growth suggests improving business momentum in pharmaceutical trading, which is positive for shareholders. However, the company remains a small-cap SME-listed entity with modest absolute earnings, so investors should weigh scale and sustainability of growth.